公司概述
LeonaBio, Inc. operates as a clinical-stage biopharmaceutical enterprise dedicated to developing small molecule therapies designed to restore neuronal health and decelerate neurodegeneration. The company functions within the Healthcare sector, specifically the Biotechnology industry, positioning it at the forefront of innovative drug discovery for neurological conditions. Its market capitalization stands at $26.62M, while the company employs a workforce of 26 individuals to advance its product pipeline. The relatively modest market cap combined with the absence of reported annual revenue figures indicates that the company remains in an early-stage development phase, relying heavily on capital markets or other financing mechanisms to fund clinical trials rather than generating significant commercial income from product sales.
财务健康
The company reports no revenue for the trailing twelve months, resulting in a net income of $-37,723,000 and an EBITDA of $-38,295,000, which reveals a cost structure dominated by research and development expenses rather than cost of goods sold. Free cash flow stands at $-30,363,876, signifying that the company is currently burning cash to fund operations and clinical progress rather than generating liquid cash from its business activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved commercial profitability or generated sales to calculate meaningful margins. Despite the negative earnings, the company holds $25.23M in cash against a debt load of $912,000, creating a debt-to-equity ratio of 3.40 that suggests a leveraged balance sheet relative to its equity base. The current ratio is an exceptionally high 9.70, which indicates robust short-term liquidity and an ability to cover current liabilities many times over with available current assets. Furthermore, the return on equity is -89.4% and the return on assets is -42.2%, metrics that reveal management is currently utilizing shareholder and asset bases to generate negative returns typical of pre-revenue biotechnology firms.
估值评估
The trailing P/E ratio is N/A due to the lack of net income, while the forward P/E is reported at -4.14, implying that the market prices in expected future earnings recovery or continued significant losses. The price-to-book ratio is 0.99, indicating that the company trades at essentially its book value with no market premium or discount relative to its net asset position. The price-to-sales ratio and EV/EBITDA are N/A or -0.04 respectively, suggesting that traditional multiple-based valuation methods are not applicable due to the absence of sales and negligible earnings before interest, taxes, depreciation, and amortization. The stock has experienced significant volatility, trading between a 52-week high of $8.36 and a 52-week low of $2.20, meaning the current price sits somewhere within this wide range reflecting high uncertainty. With a beta of 2.80, the stock exhibits high price volatility relative to the broader market, moving with greater intensity than the general equity index.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, reflecting the company's pre-commercial status where historical growth comparisons are not yet meaningful for investors. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are theoretically reinvested into growth initiatives or used to cover operational deficits. This non-dividend profile is standard for clinical-stage biotechnology companies that prioritize funding research and development over returning capital to shareholders. The overall growth and income profile is characterized by high risk and zero current income generation, relying entirely on the successful progression of its clinical pipeline to unlock future commercial value.